SEOUL: European and South Korean authorities are vying for Gilead Sciences' potential Covid-19 (coronavirus) treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is still ramping up production of the anti-viral drug.
Governments are racing to bolster supplies of remdesivir, which US regulators greenlighted this month as a treatment for the novel coronavirus. Foster City, California-based Gilead said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
